<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
  <head>
    <title>index.utf8.md</title>
    <meta charset="utf-8" />
    <link href="libs/remark-css-0.0.1/default.css" rel="stylesheet" />
    <link href="libs/remark-css-0.0.1/metropolis.css" rel="stylesheet" />
    <link href="libs/remark-css-0.0.1/metropolis-fonts.css" rel="stylesheet" />
  </head>
  <body>
    <textarea id="source">


class: inverse, middle
background-image: url(title_background.svg)
background-size: cover

&lt;font color = "white"&gt;
## Novel approaches for analysis and integration of metabolomic data
.pull-left[
### Andrew Patt
### National Center for Advancing Translational Science/Ohio State University
Biomedical Sciences Graduate Program

]

.pull-right[
.center[
&lt;img src="img/Human_metabolome_project.png" width="300px" /&gt;
]
]


---

&lt;style type="text/css"&gt;

p.caption {
  font-size: 0.6em;
}

.large { font-size: 200% }

.medium-large { font-size: 130% }

.small{ font-size: 80% }

.tiny{ font-size: 40% }

.center-left {
  position:          relative;
  top:               50%;
  transform:         translateY(50%);
}
.center-right {
  position:          relative;
  top:               50%;
  transform:         translateY(10%);
}

.remark-slide-content {
  background-color: #FFFFFF;
  border-top: 80px solid #8f1414;
  font-size: 28px;
  font-weight: 300;
  line-height: 1.5;
  padding: 1em 2em 1em 2em
}

.inverse {
  background-color: #8f1414;
  text-shadow: none;
}

.right-column {
	color: #000000;
	width: 30%;
	height: 92%;
	float: right;
}

.left-column {
  width: 68%;
  float: left;
}

&lt;/style&gt;

# Metabolomics for biomedical research


.pull-left[
- Study of small biomolecules using mass spectrometry or NMR

- Structurally and functionally diverse

- Impacted by diet, lifestyle, toxins, pharmaceutics, microbiome, etc.

- Downstream stage in flow of biological information
]

.pull-right[
&lt;img src="img/Metabolomics_schema.png" width="600px" /&gt;
]

---

# Metabolomics of Cancer

- Metabolites are the regulators and intermediates of many cellular processes relevant to cancer
--

- **Warburg Effect**

--

- **Lipogenic Phenotype**

--

- **p53 as a metabolism regulator**

--

- **MYC as a metabolism regulator**

--

- **Mutant IDH Gliomas**
  
&lt;!-- - **Warburg Effect**: increased reliance on anaerobic respiration --&gt;

&lt;!-- - **Lipogenic Phenotype**: increased endogenous *de novo* production of lipids, decrease in exogenous uptake --&gt;

&lt;!-- - **p53 as a metabolism regulator**: p53 response elements exist in promoters of glycolytic enzymes. It can also inhibit expression of glucose transporters. --&gt;

&lt;!-- - **MYC as a metabolism regulator**: induces glycolysis and glutaminolysis. Induces a hypoxic phenotype in normal oxygen environments --&gt;

&lt;!-- - **Mutant IDH Gliomas:**: Mutant IDHs convert alpha Ketoglutarate to --&gt;
&lt;!--   2-Hydroxyglutarate, which impacts the TCA cycle and induces --&gt;
&lt;!--   epigenetic changes that promote tumor progression --&gt;

---

# Dedifferentiated Liposarcoma 

.pull-left[
- 20% of all soft tissue sarcoma diagnoses
- Some drugs (Dactinomycin, Doxorubicin) are used to treat
  liposarcoma, but they have unpredictable efficacy and toxicity.
- Prognosis depends on copy number of the MDM2 oncogene
]

.pull-right[
&lt;img src="img/DDLPS_prognosis.png" width="400px" /&gt;

.tiny[
Bill KLJ, Seligson ND, Hays JL, et al. Degree of Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma. Oncologist. 2019;24(7):989-996.
]
]


---

# MDM2 inhibits DNA repair and apopotosis

.pull-left[
- Autoregulatory loop with p53

- Physically binds to p53 and catalyzes its ubiquitylation

- p53 initiates DNA repair or apoptosis if DNA repair is impossible or if telomeres have shortened too much

- Frequently inhibited in mutant p53 cancers
]

.pull-right[
&lt;img src="img/MDM2_schematic.png" width="350px" /&gt;

.tiny[
http://mcr.aacrjournals.org/content/molcanres/1/14/1001/F1.large.jpg?width=800&amp;height=600&amp;carousel=1
]
]

---

# Targeting the p53-cholesterol synthesis axis

.right-column[
.small[
- Statins (mevalonate pathway inhibitors) have been associated with
  reduced mortality in multiple cancers

- p53 downregulates transcriptional regulator of mevalonate pathway

- p53-null cell lines have been shown to withstand sterol deprived
  conditions better than WT

]
]

.left-column[

&lt;img src="img/Atorvastatin_response.png" width="800px" /&gt;

]

---

# Objectives

--

### 1. Understand resistance of MDM2 high cells to atorvastatin treatment

--

### 2. Identify altered metabolites/lipids between MDM2 high and low to identify potential biomarkers/therapeutic targets 

--

### 3. Find higher level biological differences (e.g. pathways) between MDM2 high and low tumors that explain poorer prognosis of MDM2 high patients

---

# Methods

&lt;img src="img/metabolite_methods.png" width="1000px" /&gt;

---

# Methods

&lt;img src="img/lipid_methods.png" width="1000px" /&gt;

---

# Atorvastatin did not impact MDM2 high lipidome
.pull-left[
![](index_files/figure-html/unnamed-chunk-9-1.png)&lt;!-- --&gt;
]

.pull-right[
- MDM2 high tumors have worse prognosis

- MDM2 high cell lines did not respond to atorvastatin treatment

- Analyzing the lipidome of MDM2 high cells pre and post atorvastatin
treatment revealed only 4 lipids perturbed by treatment ]

---

# Atorvastatin greatly impacted MDM2 low lipidome 

.left-column[
![](index_files/figure-html/unnamed-chunk-10-1.png)&lt;!-- --&gt;
]

.right-column[
- MDM2 low tumors have better prognosis

- The growth of MDM2 low cell lines was slowed by atorvastatin treatment

- Over a quarter of the panel was significantly altered by atorvastatin treatment ]

---

# Atorvastatin changed sphingolipids in MDM2 low cells

.left-column[
![](index_files/figure-html/unnamed-chunk-11-1.png)&lt;!-- --&gt;
]

.right-column[

- 11 ceramides and 3 hexosylated ceramides were upregulated by atorvastatin treatment in MDM2 low cells

- This could indicate activation of an apoptotic response

]

---

# Sphingolipid metabolism as a therapeutic target

&lt;img src="img/sphingolipid_therapy.png" width="1100px" /&gt;

---

# Preliminary Conclusion

## Atorvastatin may activate the sphingolipid pathway in MDM2 low cells, initiating apoptosis

--

## Hypothesis: There are baseline differences in sphingolipid levels in MDM2 high and low tumors, compromising treatment response in MDM2 high cells

---

# Lipid differences between MDM2 high and low cells

![](index_files/figure-html/unnamed-chunk-13-1.png)&lt;!-- --&gt;

---

# MDM2 high tumor cells show markers of inflammation

.pull-left[
![](index_files/figure-html/unnamed-chunk-14-1.png)&lt;!-- --&gt;
]

.pull-right[
- Increase in saturated fatty acid levels could indicate activation of lipogenesis
- Saturated fatty acids activate inflammation through TLR4/nf `\(\kappa\)` B dependent signaling
- Ac-Ser-Asp-Lys-Pro-OH prevents differentation of bone marrow stem cells into macrophages and inhibits their activation and sectretion of TNF- `\(\alpha\)`
]

---

# HexCers are upregulated by MDM2 in both panels
.pull-left[
![](index_files/figure-html/unnamed-chunk-15-1.png)&lt;!-- --&gt;
]

.pull-right[
![](index_files/figure-html/unnamed-chunk-16-1.png)&lt;!-- --&gt;
]

---


# Ceramide glycosylation levels predict MDM2 status
.left-column[
![](index_files/figure-html/unnamed-chunk-17-1.png)&lt;!-- --&gt;
.center[
![](index_files/figure-html/unnamed-chunk-18-1.png)&lt;!-- --&gt;
]
]

.right-column[
.small[
- Cell lines cluster by their expression of glycosylated ceramides in
  an unsupervised manner in the lipidomic dataset

- MDM2 high is the red bar and MDM2 low is the blue bar ]
]
---
# Preliminary Conclusion

## Metabolites different between untreated MDM2 high and MDM2 low cell lines played roles in inflammation, increased survivability, and resistance to apoptosis

--

## Does pathway analysis corroborate/extend these observations?

---
# Challenges in metabolite/lipid pathway analysis

1. Lack of pathway annotations

---

# Challenges in metabolite/lipid analysis

1. Lack of pathway annotations

.center[
&lt;img src="img/pathway_coverage.png" width="800px" /&gt;
]

---

# Challenges in metabolite/lipid pathway analysis

1. Lack of pathway annotations

	- Incorporating biological and chemical annotations offer better coverage

--

2. Metabolite panels don't cover the entire metabolome

	- Leads to reproducibility issues

--

3. Conventional pathway overrepresentation analysis does not account for redundancies of pathway annotations
	
	- Pathway annotations are not independent, which is an assumption of the Fisher's/Hypergeometric tests
---

# Addressing Issue 1: Expanding RaMP

- RaMP is our group's multiomic pathway database integrating
information from KEGG, HMDB, WikiPathways and Reactome 

--

- Integrate lipid annotations drawn from following open-source resources:
--

  - LION/Web: &gt;250,000 annotations for &gt;50,000 lipids, including lipid class, subcellular location, biological function, and biochemical/physical properties.
--

  - SwissLipids: Location, reaction, structure and chemical class annotations for 777,657 lipids (real and theoretical)
--

  - Lipid Maps: Structure and chemical class annotations for 43,636 lipids
--
  
  - LipidPedia: Disease, MeSH term, function, reactions for 4,487 lipids.
--

- Implement enrichment analysis software for lipids/metabolites

---

# Addressing Issues 2 and 3: Novel Network Method

&lt;img src="img/network_schematic1.png" width="1000px" /&gt;

---

# Addressing Issues 2 and 3: Novel Network Method

&lt;img src="img/network_schematic2.png" width="1000px" /&gt;

---

# Addressing Issues 2 and 3: Novel Network Method

&lt;img src="img/network_schematic3.png" width="1000px" /&gt;

---

# Addressing Issues 2 and 3: Novel Network Method

&lt;img src="img/network_schematic4.png" width="1000px" /&gt;

---

# Addressing Issues 2 and 3: Novel Network Method

&lt;img src="img/network_schematic5.png" width="1000px" /&gt;

---

# Addressing Issues 2 and 3: Novel Network Method

&lt;img src="img/network_schematic6.png" width="1000px" /&gt;

---

# Addressing Issues 2 and 3: Novel Network Method

&lt;img src="img/network_schematic7.png" width="1000px" /&gt;

---

# Addressing Issues 2 and 3: Novel Network Method

&lt;img src="img/network_schematic8.png" width="1000px" /&gt;

---

# Addressing Issues 2 and 3: Novel Network Method

&lt;img src="img/network_schematic9.png" width="1000px" /&gt;

---

# Addressing Issues 2 and 3: Novel Network Method

&lt;img src="img/network_schematic10.png" width="1000px" /&gt;

---

# Addressing Issues 2 and 3: Novel Network Method

&lt;img src="img/network_schematic11.png" width="1000px" /&gt;

---

# Network Method Preliminary Result

&lt;img src="img/Network_figure_2.png" width="1000px" /&gt;

---

# Conclusions

--

### 1. MDM2 was associated with resistance to apoptosis, shifts in energy metabolism, and driving a pro-inflammatory phenotype

--

### 2. Atorvastatin worked through changes in the sphingolipid pathway which were counteracted by MDM2 activity

--

### 3. Our novel pathway analysis method provided results more in line with observed biology in system than conventional method, providing partial validation 

---

# Future Directions
### 1. Extend findings to human transcriptome data
### 2. Experimentally validate findings
### 3. Network method improvements:
  - Best network topology analysis method
  - Best network fusion approach
  - How much information is appropriate to include?
  - Validate in more data sets as well as simulations

---

# Acknowledgements

.pull-left[
.small[
**Mathe Lab**
- Ewy Mathe
- Tara Eicher
- Kevin Ying
- Garrett Kinnebrew
- Kyle Spencer
- Kiran Boyinepally
- Cynthia Ramazani

**Collaborators/Advisors**
- Dr. James Chen
- Dr. Kevin Coombes
- Dr. Zachary Abrams
- Dr. Lang Li

]]

.pull-right[
.small[
**Collaborators/Advisors**
- Dr. Rachel Kopec
- Dr. Tim Garrett
- Dr. Jeremy Koelmel
- Dr. Andrew Patterson
- Dr. Philip Smith

**Funding from**
- The OSU Clinical and Translational Research Informatics Training
Program (4T15LM011270-05)
- Systems and Integrative Biology training program (T32GM068412) ]]

---

# Questions?

.pull-left[
&lt;iframe src='https://gfycat.com/ifr/LongLateAcouchi' frameborder='0' scrolling='no' allowfullscreen width='480' height='390'&gt;&lt;/iframe&gt;&lt;p&gt;&lt;a href="https://gfycat.com/discover/question-gifs"&gt;from Question GIFs&lt;/a&gt; &lt;a href="https://gfycat.com/longlateacouchi-question-mark-confused-what-huh"&gt;via Gfycat&lt;/a&gt;&lt;/p&gt;
]

.pull-right[
- Slides link: https://andyptt21.github.io

- RaMP link: https://ramp-db.bmi.osumc.edu/
]
    </textarea>
<style data-target="print-only">@media screen {.remark-slide-container{display:block;}.remark-slide-scaler{box-shadow:none;}}</style>
<script src="https://remarkjs.com/downloads/remark-latest.min.js"></script>
<script>var slideshow = remark.create({
"highlightStyle": "github",
"countIncrementalSlides": false,
"seal": false,
"ratio": "16:9"
});
if (window.HTMLWidgets) slideshow.on('afterShowSlide', function (slide) {
  window.dispatchEvent(new Event('resize'));
});
(function(d) {
  var s = d.createElement("style"), r = d.querySelector(".remark-slide-scaler");
  if (!r) return;
  s.type = "text/css"; s.innerHTML = "@page {size: " + r.style.width + " " + r.style.height +"; }";
  d.head.appendChild(s);
})(document);

(function(d) {
  var el = d.getElementsByClassName("remark-slides-area");
  if (!el) return;
  var slide, slides = slideshow.getSlides(), els = el[0].children;
  for (var i = 1; i < slides.length; i++) {
    slide = slides[i];
    if (slide.properties.continued === "true" || slide.properties.count === "false") {
      els[i - 1].className += ' has-continuation';
    }
  }
  var s = d.createElement("style");
  s.type = "text/css"; s.innerHTML = "@media print { .has-continuation { display: none; } }";
  d.head.appendChild(s);
})(document);
// delete the temporary CSS (for displaying all slides initially) when the user
// starts to view slides
(function() {
  var deleted = false;
  slideshow.on('beforeShowSlide', function(slide) {
    if (deleted) return;
    var sheets = document.styleSheets, node;
    for (var i = 0; i < sheets.length; i++) {
      node = sheets[i].ownerNode;
      if (node.dataset["target"] !== "print-only") continue;
      node.parentNode.removeChild(node);
    }
    deleted = true;
  });
})();</script>

<script>
(function() {
  var links = document.getElementsByTagName('a');
  for (var i = 0; i < links.length; i++) {
    if (/^(https?:)?\/\//.test(links[i].getAttribute('href'))) {
      links[i].target = '_blank';
    }
  }
})();
</script>

<script>
slideshow._releaseMath = function(el) {
  var i, text, code, codes = el.getElementsByTagName('code');
  for (i = 0; i < codes.length;) {
    code = codes[i];
    if (code.parentNode.tagName !== 'PRE' && code.childElementCount === 0) {
      text = code.textContent;
      if (/^\\\((.|\s)+\\\)$/.test(text) || /^\\\[(.|\s)+\\\]$/.test(text) ||
          /^\$\$(.|\s)+\$\$$/.test(text) ||
          /^\\begin\{([^}]+)\}(.|\s)+\\end\{[^}]+\}$/.test(text)) {
        code.outerHTML = code.innerHTML;  // remove <code></code>
        continue;
      }
    }
    i++;
  }
};
slideshow._releaseMath(document);
</script>
<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
(function () {
  var script = document.createElement('script');
  script.type = 'text/javascript';
  script.src  = 'https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML';
  if (location.protocol !== 'file:' && /^https?:/.test(script.src))
    script.src  = script.src.replace(/^https?:/, '');
  document.getElementsByTagName('head')[0].appendChild(script);
})();
</script>
  </body>
</html>
